Interventional

CT sign may flag who benefits from subdural hematoma procedure
By Will Morton
Among participants with the “the hyperdense capsule sign,” middle meningeal artery embolization resulted in significant benefits over usual care.
July 7, 2026
Representative axial noncontrast CT images with and without the hyperdense capsule sign (HDCS). The HDCS is defined as a hyperdense capsule layer of linear shape surrounding a subdural hematoma (SDH). (A–D) Images of SDH with the HDCS (arrowheads). (E–H) Images of SDH without the HDCS.
Microbot Medical reports over 100% revenue growth in Q2
By AuntMinnie.com staff writers
The revenue gains follow the full market release of the company's Liberty Endovascular Robotic System.
July 7, 2026
Research Money 400
VB Spine acquires CT-to-fluoroscopy technology for spine navigation
By AuntMinnie.com staff writers
The CT-Fluoro tech allows surgeons to register a patient's preoperative CT scan using standard fluoroscopic imaging.
July 7, 2026
Vb Spine Logo Purple
Egg Medical launches new radiation protection system
By AuntMinnie.com staff writers
Complete 2.0 includes a telescoping shield, upper flip shields, and reusable shielding components for scatter radiation protection during procedures.
July 6, 2026
The EggNest Complete 2.0 system.
StarMed nets FDA clearance for thyroid nodule RFA device
By AuntMinnie.com staff writers
StarMed America has received FDA clearance for the company's RFA devices for thyroid nodule treatment.
June 30, 2026
Head Neck 400
Microbot Medical taps Sanmina to manufacture Liberty system
By AuntMinnie.com staff writers
The second manufacturing site will expand production capacity and support cost reduction efforts.
June 30, 2026
Operating Room Cardiac Endovascular Adobe The Little Hut
GE HealthCare offers upgrades for interventional systems
By AuntMinnie.com staff writers
Upgraded systems also qualify for GE HealthCare's Tube Watch and OnWatch Predict service options.
June 29, 2026
Ai Logo
'Supermajority' emerges among interventional radiologists
By Will Morton
The percentage of those with a super-majority (>90%) of IR-related work more than doubled between 2008 and 2023.
June 26, 2026
Adobe Stock 310536090
Insightec highlights MRgFUS study for Parkinson's treatment
By AuntMinnie.com staff writers
Insightec is highlighting study results showing the success of MRgFUS treatment with the company's Exablate Neuro system.
June 18, 2026
Insightec’s Exablate Neuro system delivers incisionless MR-guided focused ultrasound (MRgFUS) treatment for movement disorders, including Parkinson’s disease and essential tremor.
GAE effective for knee pain up to 12 months
By Will Morton
Median numeric rating scale pain scores fell from seven at baseline to three at 12 months.
June 16, 2026
Digital subtraction angiography images of the right knee joint of a 62-year-old participant with predominantly medial knee osteoarthritis. (A) Peri-interventional image of the popliteal artery. Yellow arrow indicates the descending genicular artery, and blue arrow indicates the medial inferior genicular artery. (B, C) Selective preinterventional images show hypervascularity of two branches of the genicular artery: the (B) descending genicular artery (arrow) and the (C) medial inferior genicular artery (arrow). (D, E) Selective postinterventional images obtained after embolization with rapidly resorbable gelatin-based microspheres. Complete elimination of the blush is observed, with preserved perfusion of the proximal arterial segments.
Penumbra secures FDA clearance for stroke thrombectomy system
By AuntMinnie.com staff writers
The system is designed to detect, fatigue, and ingest clots at the site of occlusion.
June 12, 2026
Aneurysm
Image-guided focal laser ablation effective for prostate cancer
By Amerigo Allegretto
MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.
June 3, 2026
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
Page 1 of 191
Next Page